Search Results

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during their first year of life.2 Elderly people (>60 years of age) are also at an increased risk […]

Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory adapted strains of HIV were unsuccessful due to their structural dissimilarities to the native HIV […]

COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]

IMPAACT 2008 is a phase I/II, multisite, randomized open-label study which evaluates the safety and antiviral activity on HIV-1 DNA levels of VRC01 in infants living with HIV-1 beginning combination antiretroviral therapy (cART). Dr Alka Khaitan (Indiana University School of Medicine, Indianapolis, IN, USA) joins touchINFECTIOUS DISEASES to discuss the efficacy ans safety findings of […]

Each year, 160,000 infants acquire lifelong HIV infection through mother-to-child transmission (MTCT). Dr Alka Khaitan (Indiana University School of Medicine, Indianapolis, IN, USA) joins touchINFECTIOUS DISEASES to discuss the health burden and unmet needs for HIV-1 infection in infants. The presentation entitled ‘Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance […]

Following the recent results from the pivotal Phase III MELODY and Phase IIb trials of nirsevimab in the treatment of respiratory syncytial virus, we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the efficacy and safety of nirsevimab in the MELODY clinical trials and if approved, when […]

Following the recent phase III and phase IIb data for nirsevimab in the treatment of respiratory syncytial virus (RSV), we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the unmet needs in the prevention and treatment of RSV and the advantages of nirsevimab.  Questions  What are the […]

Dr Martina Penazzato (World Health Organization (WHO), Geneva, Switzerland) discusses the highlights from this year’s CROI 2022 meeting in regard to new agents for HIV and active research. The current global guideline recommendations for postnatal antiretroviral prophylaxis in vertical HIV transmission are discussed in a separate interview: Martina Penazzato, CROI 2022: Antiretrovirals for Prevention of […]

The current global guideline recommendations for postnatal antiretroviral prophylaxis in vertical HIV transmission are discussed in this interview with Dr Martina Penazzato (World Health Organization (WHO), Geneva, Switzerland). Dr Penazzato also discusses new strategies currently under investigation to reduce HIV transmission, and the challenges that still remain in translating developments in HIV transmission to a […]